FDA Brief

Warning letters Drugs

FDA warning letter to

ProRx LLC

High riskIssued Apr 7Posted May 12Center for Drug Evaluation and Research (CDER)

ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

What happened

FDA inspected ProRx LLC in Exton, PA, from September 9 to September 19, 2025, and issued a Form FDA 483 (inspection observations) and an amended Form FDA 483. FDA found sterile drug products made under insanitary conditions, including approving and distributing products after microbial contamination was recovered in the ISO 5 critical sterile production area, and found the firm compounded tirzepatide with a bulk drug substance not eligible under section 503B. The firm recalled tirzepatide and semaglutide injections on October 15, 2025, due to lack of sterility assurance.

What FDA found

  1. The firm compounded tirzepatide using a bulk drug substance that was not on FDA's list of bulk substances allowed for outsourcing facilities and was not on the drug shortage list.

    FDCA section 503B(a)(2)(A) [21 U.S.C. § 353b(a)(2)(A)]
  2. Some drug labels lacked the required “Not for Resale” statement, and a nicotinamide adenine dinucleotide injection label lacked the established name of the drug.

    FDCA section 503B(a)(10)(A)(iii)(IX) and (a)(10)(A)(iii)(II)
  3. Adverse event reporting procedures were inadequate because they did not adequately define a serious adverse event or require prompt investigation and a follow-up report within 15 calendar days.

    21 CFR 310.305(b), (c)(2); FDCA section 503B(a)(1), (b)(5)
  4. Sterile drugs were made under insanitary conditions: contamination was found in the ISO 5 critical area but products were approved and distributed, first air was blocked, stoppers were transferred without disinfection, nonsterile scissors were used, and surfaces were dirty or porous.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  5. Manufacturing quality failures included inadequate batch discrepancy investigations, environmental monitoring, aseptic procedures, quality control approval or rejection, and cleaning and disinfection.

    FDCA section 501(a)(2)(B); 21 CFR 211.192, 211.42(c)(10)(iv), 211.113(b), 211.22(c), 211.42(c)(10)(v)
  6. The drugs were unapproved new drugs and misbranded because their labeling lacked adequate directions for use.

    FDCA sections 505(a), 301(d), 502(f)(1), 301(a), 301(k)

What FDA wants

FDA asks ProRx to respond in writing within 15 working days with the specific steps taken to correct the violations and prevent recurrence, including supporting documentation; if corrections cannot be completed in that time, the firm must explain why and provide a plan.

Who should pay attention

  • clinics and patients receiving compounded tirzepatide or semaglutide
  • other 503B outsourcing facilities using bulk drug substances
  • quality teams at contract compounders making sterile injectables

This is a summary. Read the original letter on fda.gov.

ProRx LLC's FDA history

  1. ProRx, LLC

    Compounding Pharmacy/Adulterated Drug Products

Full company page

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk